115 related articles for article (PubMed ID: 22882931)
1. Does vitamin D affect disease severity in patients with ankylosing spondylitis?
Durmus B; Altay Z; Baysal O; Ersoy Y
Chin Med J (Engl); 2012 Jul; 125(14):2511-5. PubMed ID: 22882931
[TBL] [Abstract][Full Text] [Related]
2. The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis.
Mermerci Başkan B; Pekin Doğan Y; Sivas F; Bodur H; Ozoran K
Rheumatol Int; 2010 Jan; 30(3):375-81. PubMed ID: 19685057
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis.
Lange U; Jung O; Teichmann J; Neeck G
Osteoporos Int; 2001 Dec; 12(12):1031-5. PubMed ID: 11846329
[TBL] [Abstract][Full Text] [Related]
5. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.
Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
J Rheumatol; 1999 Apr; 26(4):980-4. PubMed ID: 10229432
[TBL] [Abstract][Full Text] [Related]
6. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
[TBL] [Abstract][Full Text] [Related]
7. The vitamin D status in ankylosing spondylitis in relation to intestinal inflammation, disease activity, and bone health: a cross-sectional study.
Klingberg E; Oleröd G; Hammarsten O; Forsblad-d'Elia H
Osteoporos Int; 2016 Jun; 27(6):2027-33. PubMed ID: 26809190
[TBL] [Abstract][Full Text] [Related]
8. Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis.
Lange U; Teichmann J; Strunk J; Müller-Ladner U; Schmidt KL
Osteoporos Int; 2005 Dec; 16(12):1999-2004. PubMed ID: 16172800
[TBL] [Abstract][Full Text] [Related]
9. [The reliability and validity of a Croatian version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with ankylosing spondylitis].
Grazio S; Grubisić F; Nemcić T; Matijević V; Skala H
Reumatizam; 2009; 56(2):63-76. PubMed ID: 20429263
[TBL] [Abstract][Full Text] [Related]
10. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
11. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
12. [Vitamin D levels in ankylosing spondylitis: does deficiency correspond to disease activity?].
Pokhai GG; Bandagi S; Abrudescu A
Rev Bras Reumatol; 2014; 54(4):330-4. PubMed ID: 25627231
[TBL] [Abstract][Full Text] [Related]
13. Protein oxidation status in patients with ankylosing spondylitis.
Yazici C; Köse K; Calis M; Kuzugüden S; Kirnap M
Rheumatology (Oxford); 2004 Oct; 43(10):1235-9. PubMed ID: 15292529
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
15. [Prevalence of autoantibodies directed against 1,25(OH)2D3 in patients with systemic lupus erythematosus].
Bogaczewicz J; Sysa-Jedrzejowska A; Arkuszewska C; Zabek J; Kontny E; Wozniacka A
Pol Merkur Lekarski; 2010 Feb; 28(164):103-7. PubMed ID: 20369736
[TBL] [Abstract][Full Text] [Related]
16. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
17. Is disease severity in ankylosing spondylitis genetically determined?
Hamersma J; Cardon LR; Bradbury L; Brophy S; van der Horst-Bruinsma I; Calin A; Brown MA
Arthritis Rheum; 2001 Jun; 44(6):1396-400. PubMed ID: 11407700
[TBL] [Abstract][Full Text] [Related]
18. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis.
Robertson LP; Davis MJ
Rheumatology (Oxford); 2004 Dec; 43(12):1565-8. PubMed ID: 15353608
[TBL] [Abstract][Full Text] [Related]
19. Assessment of immune status in relation to vitamin D levels in children on regular hemodialysis.
Youssef DM; Elshal AS; Abo Elazem AA
Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):267-73. PubMed ID: 22382217
[TBL] [Abstract][Full Text] [Related]
20. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
